Clinical Evaluation of Dimethyl Sulfoxide Wet Bonding Technique

Plain-language guide to NCT06635382: not phased randomized trial of DMSO (dimethyl sulfoxide, non-peptide solvent), 68 participants. Who took part, design and what was measured.

Key Facts

Registry ID: NCT06635382
Phase: not phased
Status: not yet recruiting
Start: 2024-10-20
Completion (planned or actual): 2025-02-01
Participants: 68 (estimated)
Design: randomized, double-blind, treatment
Conditions studied: Dimethyl Sulfoxide
Results posted: not yet

What This Study Did, in Plain Language

What Was Tested

The trial (not phased) is built around DMSO (dimethyl sulfoxide, non-peptide solvent).

However, there are a lack of clinical trials which prove the advantages of this technique.

The aim of the study is to clinically assess the effect of DMSO wet bonding on composite restoration in non carious cervical lesions.

It had two arms (groups): Universal single bond adhesive (active comparator) and DMSO application before Universal single bond adhesive (experimental).

The registry classes the interventions as other.

Who Took Part

Enrollment: 68 planned participants were the target.

It was open to people of any sex aged from 18 years with no upper age limit.

Healthy volunteers were not accepted; participants needed the condition being studied.

Examples of who could join: Two similar non carious cervical lesions (NCCLs) on the facial/labial surfaces of premolars. NCCLs of score 1-3 on the Smith and Knight tooth wear index. Favorable occlusion and teeth are in normal contact.

The full record lists 3 inclusion and 8 exclusion criteria; among the exclusions: NCCLs on the lingual surface; medically compromised individuals; periodontally compromised teeth.

How the Study Was Run

Design: randomized, factorial and double-blind.

The participants were allocated by chance, so the DMSO (dimethyl sulfoxide, non-peptide solvent) group and the comparison group should start out alike.

As a double-blind DMSO (dimethyl sulfoxide, non-peptide solvent) study, the assignments were hidden from both participants and investigators until the end.

Those kept unaware of assignments: participant and investigator.

It started in 2024-10-20 with completion listed for 2025-02-01.

Its stated primary purpose is treatment.

What Was Measured

Researchers chose this as the main measure: Fracture of material (time frame: From treatment to 3-6 months follow up). Marginal adaptation (time frame: From treatment to 3-6 months follow up).

What This Means in Plain Language

Put simply, this is a not phased, randomized trial of DMSO (dimethyl sulfoxide, non-peptide solvent) in 68 people.

Its status is not yet recruiting; no results are posted to the registry yet, so nothing here describes outcomes.

More context: the DMSO (dimethyl sulfoxide, non-peptide solvent) compound page, all human trials.

Our Notes on the Compound

DMSO (dimethyl sulfoxide, non-peptide solvent): A solvent that carries substances through skin and into the blood, described as a free-radical scavenger; not a peptide.

DMSO (dimethyl sulfoxide, non-peptide solvent) in the library

Source: ClinicalTrials.gov record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.